Company intelligence / Profile preview

Catamaran Bio

Cambridge, Massachusetts, United Statescatamaranbio.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

The company is developing off-the-shelf CAR-NK cell therapies and has advanced two lead CAR-NK cell therapy programs to lead optimization stage as of 2020[3]

Therapeutic areas: Oncology
Modalities: CAR-NK cell therapiesallogeneic cell therapies
Industry: Biotech

Drug pipeline

1 asset

CAT-248

Preclinical

Partnerships

OmniaBio Inc. (for development and manufacturing of allogeneic CAR-NK cell therapies)[4]

Beyond the preview

Go deeper on Catamaran Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Catamaran Bio.

Explore the full profile